BIONANO GENOMICS, INC. Financials Bionano Genomics, Inc.
Equities
BNGO
US09075F3055
Advanced Medical Equipment & Technology
|
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.814 USD | +3.55% |
|
+6.51% | -57.14% |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 32.85 | 471.8 | 864.7 | 433.5 | 73.41 | 52.56 | - | - |
| Enterprise Value (EV) 1 | 32.85 | 471.8 | 864.7 | 433.5 | 73.41 | 52.56 | 52.56 | 52.56 |
| P/E ratio | -0.62 x | -7.9 x | -11.5 x | -3.17 x | -0.28 x | -0.41 x | -0.62 x | -2.31 x |
| Yield | - | - | - | - | - | - | - | - |
| Capitalization / Revenue | 3.24 x | 55.5 x | 48.1 x | 15.6 x | 2.03 x | 1.36 x | 1.03 x | 0.71 x |
| EV / Revenue | 3.24 x | 55.5 x | 48.1 x | 15.6 x | 2.03 x | 1.36 x | 1.03 x | 0.71 x |
| EV / EBITDA | - | - | - | -3.55 x | -0.36 x | -0.76 x | -1.17 x | - |
| EV / FCF | - | - | - | - | - | - | - | - |
| FCF Yield | - | - | - | - | - | - | - | - |
| Price to Book | - | - | - | - | - | - | - | - |
| Nbr of stocks (in thousands) | 2,649 | 15,319 | 28,918 | 29,692 | 38,840 | 66,857 | - | - |
| Reference price 2 | 12.40 | 30.80 | 29.90 | 14.60 | 1.890 | 0.7861 | 0.7861 | 0.7861 |
| Announcement Date | 05/03/20 | 23/03/21 | 01/03/22 | 09/03/23 | 05/03/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 10.13 | 8.503 | 17.98 | 27.8 | 36.12 | 38.74 | 50.93 | 74.31 |
| EBITDA 1 | - | - | - | -122.1 | -201.5 | -69.4 | -45 | - |
| EBIT 1 | -25.87 | -38.55 | -77.1 | -131.7 | -215.2 | -87.2 | -68.5 | -52.61 |
| Operating Margin | -255.44% | -453.39% | -428.79% | -473.7% | -595.98% | -225.08% | -134.49% | -70.8% |
| Earnings before Tax (EBT) 1 | -29.79 | -41.08 | -78.15 | -130.7 | -232.4 | -87.7 | -69.25 | -52.61 |
| Net income 1 | -29.82 | -41.11 | -72.44 | -132.6 | -232.5 | -87.7 | -69.25 | -52.61 |
| Net margin | -294.34% | -483.43% | -402.84% | -476.93% | -643.74% | -226.37% | -135.96% | -70.8% |
| EPS 2 | -19.90 | -3.900 | -2.600 | -4.600 | -6.810 | -1.895 | -1.270 | -0.3400 |
| Free Cash Flow | - | - | - | - | - | - | - | - |
| FCF margin | - | - | - | - | - | - | - | - |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - | - | - |
| Announcement Date | 05/03/20 | 23/03/21 | 01/03/22 | 09/03/23 | 05/03/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q3 | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 4.655 | 6.302 | 5.696 | 6.67 | 7.221 | 8.215 | 7.415 | 8.662 | 9.318 | 10.72 | 8.492 | 9.066 | 9.731 | 11.45 | 11.04 |
| EBITDA 1 | -20.15 | - | -27.73 | - | - | -34.76 | -34.65 | -35.94 | -32.26 | -21.36 | -20.35 | -18.2 | -16.65 | -14.2 | -15 |
| EBIT 1 | -20.68 | -28.78 | -29.94 | -32.08 | -32.15 | -37.53 | -37.84 | -39.24 | -35.93 | -24.95 | -24.9 | -23.12 | -20.81 | -18.39 | -21.26 |
| Operating Margin | -444.21% | -456.73% | -525.68% | -480.94% | -445.22% | -456.81% | -510.36% | -452.99% | -385.62% | -232.75% | -293.28% | -254.99% | -213.82% | -160.6% | -192.51% |
| Earnings before Tax (EBT) 1 | -20.72 | -28.72 | -29.94 | -32.12 | -31.78 | -36.87 | -37.1 | -38.88 | -112.5 | -43.93 | -24.98 | -23.24 | -20.93 | -18.57 | -21.56 |
| Net income 1 | -20.75 | -22.95 | -29.95 | -32.16 | -31.81 | -38.68 | -37.12 | -38.91 | -112.6 | -43.89 | -24.98 | -23.24 | -20.93 | -18.57 | -21.56 |
| Net margin | -445.82% | -364.15% | -525.84% | -482.13% | -440.51% | -470.81% | -500.66% | -449.23% | -1,208.05% | -409.39% | -294.16% | -256.37% | -215.11% | -162.13% | -195.23% |
| EPS 2 | -0.7000 | -0.8000 | -1.100 | -1.100 | -1.100 | -1.300 | -1.200 | -1.240 | -3.220 | -0.9600 | -0.6450 | -0.5000 | -0.4475 | -0.3750 | -0.4800 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 04/11/21 | 01/03/22 | 05/05/22 | 04/08/22 | 03/11/22 | 09/03/23 | 09/05/23 | 09/08/23 | 08/11/23 | 05/03/24 | - | - | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt | - | - | - | - | - | - | - | - |
| Net Cash position | - | - | - | - | - | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - | - |
| Free Cash Flow | - | - | - | - | - | - | - | - |
| ROE (net income / shareholders' equity) | - | - | - | - | - | - | - | - |
| ROA (Net income/ Total Assets) | - | - | - | - | - | - | - | - |
| Assets 1 | - | - | - | - | - | - | - | - |
| Book Value Per Share | - | - | - | - | - | - | - | - |
| Cash Flow per Share | - | - | - | - | - | - | - | - |
| Capex 1 | - | - | - | 2.41 | 1.69 | 3 | 4 | - |
| Capex / Sales | - | - | - | 8.66% | 4.68% | 7.74% | 7.85% | - |
| Announcement Date | 05/03/20 | 23/03/21 | 01/03/22 | 09/03/23 | 05/03/24 | - | - | - |
1USD in Million
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
D+
Sell
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
0.7861
USD
Average target price
6.667
USD
Spread / Average Target
+748.07%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -57.14% | 52.56M | |
| +8.14% | 219B | |
| +6.80% | 183B | |
| +11.39% | 133B | |
| +26.05% | 108B | |
| +1.44% | 63.06B | |
| +12.22% | 52.02B | |
| -0.62% | 48.2B | |
| -0.47% | 40.37B | |
| +13.00% | 39.35B |
- Stock Market
- Equities
- BNGO Stock
- Financials Bionano Genomics, Inc.
